The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Devraj SukulMilan SethTheodore SchreiberGeorge HanzelAkshay KhandelwalLouis A CannonThomas A LalondeHitinder S GurmPublished in: Journal of interventional cardiology (2017)
Despite being contraindicated in dialysis, eptifibatide was used approximately 3.5 times more frequently than abciximab among dialysis patients undergoing PCI but was associated with similar in-hospital outcomes.
Keyphrases
- end stage renal disease
- chronic kidney disease
- peritoneal dialysis
- percutaneous coronary intervention
- patients undergoing
- acute coronary syndrome
- acute myocardial infarction
- coronary artery disease
- st segment elevation myocardial infarction
- antiplatelet therapy
- st elevation myocardial infarction
- coronary artery bypass grafting
- newly diagnosed
- atrial fibrillation
- ejection fraction
- healthcare
- heart failure
- emergency department
- adipose tissue
- skeletal muscle
- left ventricular
- coronary artery bypass
- adverse drug
- insulin resistance